Prodrug Ester Derivatives for mGlu2/3 Receptor Antagonist Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing prodrugs that effectively enhance the oral absorbability and in vivo exposure of (1R,2R,3R,5R,6R)-2-amino-6-fluoro-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives and (1S,2R,3R,5R,6S)-2-amino-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives, which act as antagonists of mGlu2 and mGlu3 receptors, while maintaining chemical stability and biotransformation efficiency.
Innovation Solution
Formulating ester derivatives of these compounds that are stable in gastric and intestinal solutions and convertible to active forms in liver S9 fractions, enhancing membrane permeability and rapid conversion to active forms after absorption, thereby increasing their antagonistic effect on group 2 metabotropic glutamate receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the chemical structure of (1R,2R,3R,5R,6R)-2-amino-6-fluoro-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives is used directly, then the compound has strong antagonistic activity on mGlu2 and mGlu3 receptors, but the oral absorbability is poor
Solution Approach 1:
The patent introduces a prodrug form as an intermediary substance that temporarily masks the poor absorbability issue. The prodrug contains the active compound conjugated with a carrier molecule that improves membrane permeability. After oral administration, the prodrug is hydrolyzed by esterases in the body to release the active antagonist, thus mediating between the need for oral administration and the need for receptor activity
Solution Approach 2:
The patent changes the chemical parameters of the compound by converting it to a prodrug form with modified physical-chemical properties. The prodrug has improved lipophilicity and membrane permeability compared to the parent compound, while maintaining the ability to be converted back to the active form in vivo through enzymatic hydrolysis
2Ease of operation
If a prodrug form is developed to improve oral absorbability, then the membrane permeability is enhanced, but the chemical stability may be compromised
Solution Approach 1:
Instead of trying to make the active compound itself more stable while improving permeability, the patent inverts the approach by creating a prodrug that is stable enough for administration but designed to be unstable in the right place and time - it is hydrolyzed by esterases in the gastrointestinal tract or plasma to release the active compound. This inversion transforms the stability problem into a controlled degradation feature
Solution Approach 2:
The prodrug design allows the active compound to 'skip' the absorption barrier by being incorporated into a more permeable molecular structure. The prodrug rushes through the membrane quickly, then rapidly converts to the active form, minimizing the time the modified structure needs to remain stable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The prodrug ester derivatives exhibit improved oral absorbability and rapid conversion to active forms, enhancing their antagonistic effect on mGlu2 and mGlu3 receptors, leading to increased in vivo exposure and efficacy in treating neuropsychiatric and neurological disorders.
Implementation Method 1
it has become clear that compounds (active forms) acting as antagonists of mGlu2 and mGlu3 receptors enhance the oral absorbability and increase the in vivo exposure of the active forms
Implementation Method 2
Prodrugs of (1R,2R,3R,5R,6R)-2-amino-6-fluoro-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives and (1S,2R,3R,5R,6S)-2-amino-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives
Data Source
AI summary
Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune- related diseases, and so on.